The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia
Open accessAbstract
BACKGROUND: Allogeneic or autologous bone marrow transplantation and intensive consolidation chemotherapy are used to treat acute myelogenous leukemia in a first complete remission. METHODS: After induction treatment with daunorubicin and cytarabine, patients who had a complete remission received a first course of intensive consolidation chemotherapy, combining intermediate-dose cytarabine and amsacrine. Patients with an HLA-identical sibling were assigned to undergo allogeneic bone marrow transplantation; the others were randomly assigned to undergo autologous bone marrow transplantation (with unpurged bone marrow) or a second course of intensive chemotherapy, combining high-dose cytarabine and daunorubicin. Comparisons were made on the basis of the intention to treat. RESULTS: A total of 623 patients had a complete remission; 168 were assigned to undergo allogeneic bone marrow transplantation, and 254 were randomly assigned to one of the other two groups. Of these patients, 343 completed the treatment assignment: 144 in the allogeneic-transplantation group, 95 in the autologous-transplantation group, and 104 in the intensive-chemotherapy group. The relapse rate was highest in the intensive-chemotherapy group and lowest in the allogeneic-transplantation group, whereas the mortality rate was highest after allogeneic transplantation and lowest after intensive chemotherapy. The projected rate of disease-free survival at four years was 55 percent for allogeneic transplantation, 48 percent for autologous transplantation, and 30 percent for intensive chemotherapy. However, the overall survival after complete remission was similar in the three groups, since more patients who relapsed after a second course of intensive chemotherapy had a response to subsequent autologous bone marrow transplantation. Other differences were also observed, especially with regard to hematopoietic recovery (it occurred later after autologous transplantation) and the duration of hospitalization (it was longer with bone marrow transplantation). CONCLUSIONS: Autologous as well as allogeneic bone marrow transplantation results in better disease-free survival than intensive consolidation chemotherapy with high-dose cytarabine and daunorubicin. Transplantation soon after a relapse or during a second complete remission might also be appropriate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of Ranks in One-Criterion Variance Analysis
Kruskal, W. H., & Wallis, W. A. (1952) · Journal of the American Statistical Association · doi:10.1080/01621459.1952.10483441 · Cited by 13,912
Bone marrow transplant: Angela Joyce on the care of children undergoing BMT for genetic disorders
Joyce, A. (1989) · Paediatric Nursing · doi:10.7748/paed.1.6.21.s21 · Cited by 3,384
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, D. A. G., GRALNICK, H. R., & SULTAN, C. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-620 · Cited by 2,926
Graft-versus-leukemia reactions after bone marrow transplantation
Horowitz, M., Gale, R., Sondel, P., Goldman, J., Kersey, J., Kolb, H., Rimm, A., Ringden, O., Rozman, C., & Speck, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,774
TAN, P. (2001) · A Clinical Approach to Medicine · doi:10.1142/9789810248178_0024 · Cited by 2,697
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Santos, G. W., Tutschka, P. J., Brookmeyer, R., Saral, R., Beschorner, W. E., Bias, W. B., Braine, H. G., Burns, W. H., Elfenbein, G. J., Kaizer, H., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312013092202 · Cited by 809
Fenaux, P., Le Deley, M., Castaigne, S., Archimbaud, E., Chomienne, C., Link, H., Guerci, A., Duarte, M., Daniel, M., & Bowen, D. (1993) · Blood · doi:10.1182/blood.v82.11.3241.3241 · Cited by 516
Büchner, T., Urbanitz, D., Hiddemann, W., Rühl, H., Ludwig, W. D., Fischer, J., Aul, H. C., Vaupel, H. A., Kuse, R., & Zeile, G. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.12.1583 · Cited by 362
Varying intensity of postremission therapy in acute myeloid leukemia
Cassileth, P., Lynch, E., Hines, J., Oken, M., Mazza, J., Bennett, J., McGlave, P., Edelstein, M., Harrington, D., & O'Connell, M. (1992) · Blood · doi:10.1182/blood.v79.8.1924.1924 · Cited by 296
Gorin, N., Aegerter, P., Auvert, B., Meloni, G., Goldstone, A., Burnett, A., Carella, A., Korbling, M., Herve, P., & Maraninchi, D. (1990) · Blood · doi:10.1182/blood.v75.8.1606.1606 · Cited by 279
Cancer Clinical Trials: Methods and Practice.
Freedman, L. S., Buyse, M. E., Staquet, M., et al. (1985) · Biometrics · doi:10.2307/2531305 · Cited by 209
Cerebellar toxicity with high-dose cytosine arabinoside.
Herzig, R. H., Hines, J. D., Herzig, G. P., Wolff, S. N., Cassileth, P. A., Lazarus, H. M., Adelstein, D. J., Brown, R. A., Coccia, P. F., & Strandjord, S. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.6.927 · Cited by 162
CHAMPLIN, R. E., HO, W. G., GALE, R. P., WINSTON, D., SELCH, M., MITSUYASU, R., LENARSKY, C., ELASHOFF, R., ZIGHELBOIM, J., & FEIG, S. A. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-102-3-285 · Cited by 160
A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia
Cassileth, P. A., Begg, C. B., Bennett, J. M., Bozdech, M. J., Kahn, S., Weiler, C., & Jh, G. (1984) · Blood · doi:10.1182/blood.v63.4.843.843 · Cited by 147
Wolff, S. N., Herzig, R. H., Fay, J. W. J., Phillips, G. L., Lazarus, H. M., Flexner, J. M., Stein, R. S., Greer, J. P., Cooper, B., & Herzig, G. P. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1260 · Cited by 143
Löwenberg, B., Verdonck, L. F., Dekker, A. W., Willemze, R., Zwaan, F. E., de Planque, M. M., Abels, J., Sonneveld, P., der Lelie, J. V., & Goudsmit, R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.287 · Cited by 133
Self-citationGorin, N. C., Labopin, M., Meloni, G., et al. (1991) · PubMed · Cited by 132
Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia.
Clift, R. A., Buckner, C. D., Appelbaum, F. R., Schoch, G. H., Petersen, F. B., Bensinger, W., Sanders, J., Sullivan, K. M., Storb, R. F., & Singer, J. W. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1723 · Cited by 123
Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.
Preisler, H. D., Raza, A., Early, A., et al. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.5.722 · Cited by 90
Schiller, G. J., Nimer, S. D., Territo, M., et al. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.41 · Cited by 75
RAPID-ONSET STEROID PSYCHOSIS WITH VERY LOW DOSAGE OF PREDNISOLONE
Greeves, J. A. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92528-5 · Cited by 62
Treatment of the Newly Diagnosed Adult with De Noyo Acute Myeloid Leukemia
Stone, R. M., & Mayer, R. J. (1993) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30257-0 · Cited by 49
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
Stone, R. M., & Mayer, R. J. (1993) · PubMed · Cited by 47
Cancer Clinical Trials: Methods and Practice
Freireich, E. J. (1985) · JAMA · doi:10.1001/jama.1985.03350340120038 · Cited by 45
Begg, C. B., McGlave, P. B., Bennett, J. M., Cassileth, P. A., & Oken, M. M. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.5.369 · Cited by 39
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Harousseau, J., Milpied, N. J., Brière, J., et al. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.8.1432 · Cited by 37
Short-term therapy for acute myelogenous leukemia.
Rohatiner, A. Z. S., Gregory, W. M., Bassan, R., Barnett, M. J., Waxman, J., Richards, M. A., Ganesan, T. S., Tucker, J., Malik, S., & Biruls, R. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.218 · Cited by 36
Mayer, R. J. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.10.1532 · Cited by 36
Cited by
Slovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation
Socié, G., Stone, J. V., Wingard, J. R., Weisdorf, D., Henslee-Downey, P. J., Bredeson, C., Cahn, J.-Y., Passweg, J. R., Rowlings, P. A., Schouten, H. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907013410103 · Cited by 698
Drug therapy for acute myeloid leukemia
Tallman, M. S., Gilliland, D. G., & Rowe, J. M. (2005) · Blood · doi:10.1182/blood-2005-01-0178 · Cited by 661
Cassileth, P. A., Harrington, D. P., Appelbaum, F. R., Lazarus, H. M., Rowe, J. M., Paietta, E., Willman, C., Hurd, D. D., Bennett, J. M., Blume, K. G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812033392301 · Cited by 609
Metadata
- Authors
- Zittoun, R. A., Mandelli, F., Willemze, R., de Witte, T., Labar, B., Resegotti, L., Leoni, F., Damasio, E., Visani, G., Papa, G., Caronia, F., Hayat, M., Stryckmans, P., Rotoli, B., Leoni, P., Peetermans, M. E., Dardenne, M., Vegna, M. L., Petti, M. C., Solbu, G., & Suciu, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-01-26
- Volume
- 332
- Issue
- 4
- Pages
- 217-223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2013051826
- Cited by
- 849
- References
- 29
- FWCI
- 27.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.